Benzinga · Jul 30, 2026
BGM Group Announces Chairman And Co-CEO Chen Xin Resigns, Effective July 30, 2026; Zhanchang Xin Appointed As New Chairman Of Board; Hong Li Named As Co-Chief Executive Officer
-SEC Filing
BG
NASDAQ · BGM
BGM Group Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.24
Down-$0.01 (-3.50%)
Updated Sep 26, 2026, 9:54 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.18B
- P/E ratio
- -29.55
- Dividend yield
- 0.00%
- 52-week range
- $0.23 – $1.08
- Volume
- 189.64K
- Avg. volume
- 36.41K
Price performance
BGM price history
1M range · 20 trading sessions · Daily adjusted prices
BGM closed at $0.24 after 20 trading sessions, down 26.72% for the selected period.
- Last close
- $0.24
- Period change
- -26.72%
- Period low
- $0.24
- Period high
- $0.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $0.244 | $0.278 | $0.2301 | $0.24 | 189.64K |
| Sep 24, 2026 | $0.26 | $0.26 | $0.2486 | $0.2487 | 34.68K |
| Sep 23, 2026 | $0.2563 | $0.265 | $0.2501 | $0.255 | 71.24K |
| Sep 22, 2026 | $0.26 | $0.265 | $0.2459 | $0.2579 | 14.1K |
| Sep 21, 2026 | $0.2494 | $0.2699 | $0.2494 | $0.256 | 58.49K |
| Sep 18, 2026 | $0.25 | $0.2713 | $0.25 | $0.251 | 38.83K |
| Sep 17, 2026 | $0.251 | $0.2732 | $0.2341 | $0.259 | 48.08K |
| Sep 16, 2026 | $0.2471 | $0.27 | $0.2425 | $0.2579 | 51.44K |
| Sep 15, 2026 | $0.259 | $0.2899 | $0.2471 | $0.2472 | 51.6K |
| Sep 14, 2026 | $0.26 | $0.26 | $0.2425 | $0.2546 | 18.47K |
| Sep 11, 2026 | $0.289 | $0.2984 | $0.263 | $0.263 | 39.58K |
| Sep 10, 2026 | $0.2751 | $0.3049 | $0.2731 | $0.2756 | 137.16K |
| Sep 9, 2026 | $0.284 | $0.33 | $0.273 | $0.2731 | 126K |
| Sep 8, 2026 | $0.2907 | $0.32 | $0.29 | $0.2905 | 60.82K |
| Sep 4, 2026 | $0.2701 | $0.285 | $0.2701 | $0.285 | 14.78K |
| Sep 3, 2026 | $0.271 | $0.285 | $0.26 | $0.283 | 42.23K |
| Sep 2, 2026 | $0.273 | $0.2799 | $0.2603 | $0.2797 | 45.21K |
| Sep 1, 2026 | $0.265 | $0.2824 | $0.265 | $0.2729 | 32.19K |
| Aug 31, 2026 | $0.3177 | $0.3199 | $0.2601 | $0.2719 | 247.24K |
| Aug 28, 2026 | $0.2827 | $0.33 | $0.27 | $0.3275 | 894.12K |
Latest BGM news
The latest Smart Investors Daily articles mentioning BGM.
Stock researchCompany · Overview
BGM research
Overview
Company profile and research snapshot.
Company profile
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Feb 26, 2026
BGM Group Receives Nasdaq Noncompliance Notice, Gets 60 Days To Regain Compliance
BGM Group Ltd. (NASDAQ: BGM) (the "Company" or "BGM") announced on February 24, 2026, that it has received a notification (the "Notification") from the Listing Qualifications Department of The Nasdaq Stock Market
seekingalpha.com · Sep 24, 2025
BGM Group: I Think I Found An Undervalued Stock
32.7% of BGM's revenue is now from high-growth AI, pushing profit up 78%. Yet, the market still values it like a slow-moving API business. With β ≈ 0.04–0.05 and basically no leverage, you get CAPM ≈ 4.42% and WACC ≈ 4.41%, that math checks out. On my assumptions, the DCF lands at about $19.07 per share. Versus the current $8.93, that's roughly +113% upside—consistent with the "undervalued" call.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
